Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Trends in Corporate Consolidation Reflect in Biden’s Healthcare Anti-Trust Action

Earlier this month, President Joe Biden signed an executive order that addresses competition among hospitals, health insurers, prescription drugmakers, and hearing aid manufacturers in an effort to tackle anti-competitive practices in various industries. The order urges the Department of Justice and the Federal Trade Commission to crack down on antitrust laws and actively revise merger…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Earlier this month, President Joe Biden signed an executive order that addresses competition among hospitals, health insurers, prescription drugmakers, and hearing aid manufacturers in an effort to tackle anti-competitive practices in various industries.

The order urges the Department of Justice and the Federal Trade Commission to crack down on antitrust laws and actively revise merger guidelines to ensure patient safety. However, how will these actions impact mergers and acquisitions in general?

To further investigate this question, as well as to evaluate the incentives behind corporate consolidation in today’s economy, Daniel Litwin, the Voice of B2B, invited Dr. Susan Clark Muntean, associate professor of management and accountancy at UNC Asheville, to this episode of MarketScale TV.

The two consider what impact the trends toward M&As have had on patient access to healthcare, as well as who typically benefits from corporate mergers and acquisitions in the long term.

“That question should always be asked to look at projected outcomes and the impact of mergers and acquisitions. Who benefits, who doesn’t, and who is harmed or potentially could be harmed,” explains Dr. Clark Muntean.

They also discuss some of the responses from industry organizations to the executive order, how the primary motivators for corporate consolidation have evolved over the years and the overall effectiveness of anti-trust regulations in combatting anti-competitive practices.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits now take 3–5+ years of prep. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com closed $220 million in equity and debt. It’s expanding its U.S. imaging network plus API-based scheduling and results delivery. For health plans and employers, imaging is starting to look like a platform procurement and integration decision, not a directory problem.

  • 01If imaging access is bought via an API, the real spec becomes integration depth: two-way scheduling plus results routing into the EMR, according to Business Wire.
  • 02Scan.com’s mix of $90M equity and $130M debt earmarked for M&A and working capital points to a fast-changing imaging provider network, which can help access but demands discipline in contracting and integration testing.
  • 03The same week’s funding news for Elucid ($55M) suggests AI imaging vendors will keep pushing toward FDA-cleared workflow insertions, a different buying path than network-layer platforms.

Sep 4, 2026

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitor messaging suggests compliance testing and AI-ready compute are becoming early decisions, not afterthoughts. Medical Economics described 2026 as a period shaped by rapid technological change, regulatory scrutiny and ongoing economic uncertainty. Medical Design & Outsourcing’s MD&M West 2026 preview points to exhibitors highlighting test equipment, contract manufacturing and other launch support services.

  • 01If a device roadmap includes AI features, the critical path shifts toward data and software evidence that regulators can audit, which means earlier lock-in of compute platforms and test plans, pulling verification and validation into supplier selection.
  • 02MD&M West exhibitor messaging suggests verification and validation capacity is becoming a procurement problem, with rentals and lab-ready gear positioned as a way to avoid booking delays and re-tests, according to Medical Design & Outsourcing.
  • 03With imaging and other new procedural and device concepts moving fast, manufacturing leaders should expect more frequent line-change decisions and component qualification work, as GE HealthCare's photon-counting CT CE mark reported by MedTech Dive and MDDI's New Technologies coverage illustrate.

Sep 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512